News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

Cintredekin besudotox in treatment of malignant glioma.


Posted on: 06/04/2008

Expert Opin Biol Ther. 2008 Jun;8(6):805-812. Related Articles


Cintredekin besudotox in treatment of malignant glioma.

Mut M, Sherman JH, Shaffrey ME, Schiff D.

1Assistant Professor Hacettepe Hastanesi Beyin Cerrahisi, Bolum 71 Sihhiye, Ankara 06100, Turkey +90 312 3108495 ; +90 312 3111131 ; mm2ee@virginia.edu , 2Resident University of Virginia, Department of Neurosurgery, Charlottesville, VA, USA, 3Professor University of Virginia, Department of Neurosurgery, Division of Neuro-oncology, Charlottesville, VA, USA, 4Professor University of Virginia, Department of Neurology, Division of Neuro-oncology, Charlottesville, VA, USA.

Background: Interleukin-13 (IL-13) receptors are overexpressed in glioblastoma multiforme (GBM). The presence of IL-13 binding sites in GBM and their absence in normal brain tissue validates IL-13 receptor as an important target in human GBM. Objective: This review discusses the bench-to-bedside experience with a recombinant cytotoxin composed of human IL-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR), delivered via convection-enhanced delivery (CED), in GBM treatment. Methods: The authors review publications regarding the laboratory research and clinical development of IL-13-directed therapies and summarize the future of IL-13-targeted cytotoxin. Conclusion: The IL-13 receptor remains an important potential target in GBM, and preliminary experience with the IL-13-PE38QQR cytotoxin (also called cintredekin besudotox) has helped to pave the way for study of CED as an important means of drug delivery to malignant gliomas. Ongoing analysis of recently completed clinical trials will determine the future of this agent and its potential therapeutic targets.

PMID: 18476792 [PubMed - as supplied by publisher]

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740